HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Turns Kratom's Future In US Dietary Supplement Market Into History

This article was originally published in The Rose Sheet

Executive Summary

FDA Commissioner Scott Gottlieb says kratom's apparently increasing use "as an alternative or adjunct to opioid use" has made enforcement on the ingredient more of a priority for FDA, and "given the scope of this crisis, we must do more."


Related Content

Kratom Industry GMPs Target Swaying FDA By Exceeding Agency Standards
Kratom Group Sharpens Criticism Of 'Opioid' Finding In FDA's Report To DEA
Failed NDIs, FDA's Opioid Concerns Don't Stop Kratom Supplement Sales
Poppy Seed Tea Latest Catch In FDA Enforcement Net For Opioid Claims
Salmonella In Kratom, Like Use Of The Herb, Exceeds FDA Expectations
Kratom: All Questions On Pre-DSHEA Ingredient Evidence In One Package
Controversy Brews With 'Inaccurate' Reports Linking Kratom To Deaths
DEA Proposal To Schedule Kratom Stirs Wave Of Opposition
Kratom Reprieve From Scheduling Requested By House Members
Kratom Import Alert Clarifies FDA Deems The Botanical An Unsafe NDI





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts